PRTA Strangle Strategy
PRTA (Prothena Corporation plc), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
PRTA (Prothena Corporation plc) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $502.6M, a beta of -0.23 versus the broader market, a 52-week range of 4.32-11.8, average daily share volume of 505K, a public-listing history dating back to 2012, approximately 163 full-time employees. These structural characteristics shape how PRTA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of -0.23 indicates PRTA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on PRTA?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current PRTA snapshot
As of May 15, 2026, spot at $9.80, ATM IV 81.10%, IV rank 14.28%, expected move 23.25%. The strangle on PRTA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on PRTA specifically: PRTA IV at 81.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a PRTA strangle, with a market-implied 1-standard-deviation move of approximately 23.25% (roughly $2.28 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated PRTA expiries trade a higher absolute premium for lower per-day decay. Position sizing on PRTA should anchor to the underlying notional of $9.80 per share and to the trader's directional view on PRTA stock.
PRTA strangle setup
The PRTA strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With PRTA near $9.80, the first option leg uses a $10.29 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed PRTA chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 PRTA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $10.29 | N/A |
| Buy 1 | Put | $9.31 | N/A |
PRTA strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
PRTA strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on PRTA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on PRTA
Strangles on PRTA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the PRTA chain.
PRTA thesis for this strangle
The market-implied 1-standard-deviation range for PRTA extends from approximately $7.52 on the downside to $12.08 on the upside. A PRTA long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current PRTA IV rank near 14.28% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on PRTA at 81.10%. As a Healthcare name, PRTA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to PRTA-specific events.
PRTA strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. PRTA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move PRTA alongside the broader basket even when PRTA-specific fundamentals are unchanged. Always rebuild the position from current PRTA chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on PRTA?
- A strangle on PRTA is the strangle strategy applied to PRTA (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With PRTA stock trading near $9.80, the strikes shown on this page are snapped to the nearest listed PRTA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are PRTA strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the PRTA strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 81.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a PRTA strangle?
- The breakeven for the PRTA strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current PRTA market-implied 1-standard-deviation expected move is approximately 23.25%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on PRTA?
- Strangles on PRTA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the PRTA chain.
- How does current PRTA implied volatility affect this strangle?
- PRTA ATM IV is at 81.10% with IV rank near 14.28%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.